15 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: ResMed, Australian developer, manufacturer and distributor of sleep and respiratory medical equipment, has launched Narval CC, its state-of-the-art mandibular repositioning device in the US. Narval CC is an innovative, effective, world-class device that offers an alternative solution to patients for snoring and obstructive sleep apnea.
ResMed's introduction of Narval CC follows its acquisition of the France-based Laboratoires Narval. With the acquisition, ResMed added an additional therapy method to complement its comprehensive positive airway pressure solutions, providing a broader offering for snoring and obstructive sleep apnea sufferers.
"Obstructive sleep apnea is a severe disease which, if left untreated, can have significant long-term impacts on serious conditions including heart disease, type 2 diabetes, obesity, chronic obstructive pulmonary disease, and, as very recent research has shown, cancer," said Mr Michael Farrell, president, ResMed Americas. "The gold-standard therapy for obstructive sleep apnea is PAP therapy. However, we know that today some patients either refuse PAP treatment or fail to comply. Narval CC provides an effective alternative for those untreated patients. With the release of Narval CC, ResMed is now the only PAP company with a customized solution for noncompliant patients or patients who refuse PAP treatment, giving our customers and patients another choice in their treatment."